New US Subsidiary to be located in the
"I would like to take this opportunity to thank
Dr Broom, newly appointed Chief Executive Officer of Nabriva, added: "New antibiotic development is one of the most important priorities in medicine as we see increasing resistance to currently available drugs. Nabriva is one of a few development stage companies with a truly novel antibiotic product ready for phase 3 studies in an area of significant unmet medical need, and with a clear development path to potential approval. I am very excited to join Nabriva at this stage and look forward to working with the highly experienced board and management team on building a patient-centric global biopharmaceutical company. My immediate attention is focussed on establishing a world-class clinical development team in the
Notes to editors
Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics, the pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens. Nabriva's world-class medicinal chemistry expertise has achieved an industry first with the development of both intravenously administered and orally available pleuromutilins that are therefore ideal for i.v. to oral switch therapy.
Nabriva's lead product lefamulin (BC-3781) is about to enter Phase 3 clinical studies. Due to its broad spectrum, oral and i.v. formulations, and a favourable safety profile, lefamulin is the first of a new class of antibiotics ideally positioned for the treatment of community-acquired bacterial pneumonia (CABP), plus hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as acute bacterial skin and skin structure infections (ABSSSI), with potential in several other indications (sexually transmitted infections including MDR gonorrhoea; osteomyelitis) including paediatric use.
Nabriva's preclinical program, the Extended Spectrum Pleuromutilins (ESPs) expands the activity of pleuromutilins to include major enteric Gram-negative pathogens such as E. coli and K. pneumoniae. The targeted indications for the ESP extend beyond the current use of the first-generation pleuromutilins, thereby filling important gaps in treatment options of both marketed antibiotics and compounds in development.
For further information, please contact:
Most Popular Stories
- Pickup Discounts Boost September Auto Sales
- Kurdish Militia Still Lack Weapons, Training
- Review: Pay by Phone or Just Keep Using Plastic?
- Lexus Luxury Compact Sedan Wins Buyers
- Ebola Victim Was Sent Home by Dallas Hospital
- N.Y. Ups Awards of State Contracts to Minorities
- Dallas Parents Fear Students Exposed to Ebola
- Group Offers Online Help for College Students
- Baker Hughes to Disclose Fracking Chemicals
- Why the Bond Market Isn't as Safe as You Think